Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen

Executive Summary

Manufactured "over 500,000 doses of recombinant DNA products" in fiscal 1987 (year ended March 31) at its GMP facility, a more than tenfold increase over the previous year, firm's most recent annual report notes. Company is doubling existing capacity with a 20,000 sq. ft. mammalian cell culture facility at its Thousand Oaks, California site, scheduled for completion in the current fiscal year. Firm also plans a 1988 product license application filing for its erythropoietin product EPO.
Advertisement
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS012230

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel